Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 1999

View Archived Issues

Pfizer: Q4 1998 highlights

Alza's 1998 milestones, priorities for 1999

LeukoSite acquisition of CytoMed completed

Company Profile: Pentagenic Pharmaceuticals

Ariad achieves second milestone in HMR collaboration

Second U.S. patent allowed for Antex Biologics' H. pylori vaccine

Incyte and ICAgen collaborate on ion channel R&D

NO synthase inhibition reduces chronic tension headache pain

Idec Pharmaceuticals announces three new cancer research collaborations

Available for licensing from VUFB: dopamine agonist for dermatology, gastrointestinal indications

Novel antihypertensive drug candidate available for licensing from VUFB

FDA approves Chiron's newest HCV diagnostic test

Genzyme's oncology division in-licenses angiogenesis inhibitor for development

Biostar initiates phase I/II trial of Norelin in prostate cancer patients and creates subsidiary

Isis Pharmaceuticals: Q4 and year-end 1998 highlights

Dopamine D4-selective compounds, therapeutic and diagnostic uses disclosed by Resolution

Potent bradykinin antagonists developed at Fournier

Boehringer Ingelheim researches thrombin inhibitors

Protein farnesyltransferase inhibitors in development at Bristol-Myers Squibb

Novel antioxidant/antiproliferative NSAID esters and amides designed by Alcon

New test for Lyme disease approved by FDA

Astra's P2T receptor antagonists offer significant potential as novel antithrombotics

Quark Biotech enters research agreement with Sankyo for diabetes drug

Lilly cancels Targretin development program in diabetes with Ligand

New broad-based malaria vaccine shows positive results